Search
From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic
CEO Elias Paptheodorou walks us through the data and descirbes how this has already been tested (for safety) in five cancer patients who had small portions of their liver resected. The next step is to test it in patients with major resections, and also a randomized phase 2a, both of which the company already has the cash to fund.
18 hours ago
BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C
CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is...
Nov 4, 2024
.png){kind=logo}
